BioMed Realty and TransMedics Announce 498,000-Square-Foot Lease at Assembly Innovation Park

SAN DIEGO & SOMERVILLE, Mass.--(BUSINESS WIRE)--BioMed Realty, the largest privately-owned operator of real estate for the life science and technology industries, and TransMedics Group, Inc. (“TransMedics”, ticker: TMDX), a publicly traded medical technology company transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that TransMedics has entered into a full building, 498,000-square-foot lease at Assembly Innovation Park, a premier life sciences development in Somerville, Massachusetts developed by BioMed Realty.

The recently constructed 12-story commercial research and development facility will serve as TransMedics’ new global headquarters and manufacturing hub. The building, which is LEED^® Platinum and WELL certified, was specifically constructed to support both operational efficiency and workforce wellbeing. In addition to leasing 100% of the newly developed building for 16 years, TransMedics acquired the adjacent land parcel and portion of the parking structure within the campus to support future growth.

“We selected our new headquarters to support the full scale and complexity of our mission,” said Waleed Hassanein, M.D., President and CEO of TransMedics. "Our innovation will accelerate and thrive in this world-class facility that BioMed Realty built. It provides the infrastructure, flexibility, and long-term growth capacity we need to support our teams and the broader transplant community as we continue to advance life-saving transplant technologies and scale our impact globally.”

For more than 20 years, BioMed Realty has specialized in serving innovative life science companies, drawing on over 250 years of seasoned executive experience, to design a best-in-class building with an exceptional amenity package, large floor plates and an ability to accommodate robust programming requirements.

Bill Kane, President, East Coast and U.K. Markets at BioMed Realty, said: "We are delighted to welcome TransMedics to BioMed Realty’s highly differentiated Assembly Innovation Park campus. Led by our team of multidisciplinary experts, BioMed’s hands-on approach allows us to create and manage spaces that support our tenants’ most strategic initiatives."

Situated in Somerville’s mixed-use urban development area known as Assembly Square, and with its close proximity to Interstate 93 and the MBTA Orange Line, Assembly Innovation Park offers exceptional access and visibility to Greater Boston’s leading academic institutions, clinical centers and life sciences talent base.

In addition, Colleen O’Connor, Executive Vice President, Market Lead, East Coast & UK Markets at BioMed Realty, said: “At BioMed Realty, our purpose is to deliver mission-critical infrastructure that enables innovators to focus on advancing technology to improve human health. The Assembly Innovation Park campus was designed to provide flexibility and operational resilience that companies like TransMedics need to accelerate innovation and change lives.”

About BioMed Realty
BioMed Realty is the largest privately owned operator of real estate for the life science and technology industries in the United States and United Kingdom. The Company operates 17.3 million square feet of purpose-built laboratory and office space across the world’s top innovation hubs, including Boston/Cambridge, San Francisco, San Diego, Seattle, Boulder, and Cambridge, U.K. With an additional 1.5 million square feet of Class A properties under development, BioMed Realty delivers flexible, reliable, and sustainable environments designed to accelerate discovery and keep world-changing work moving. Backed by more than 20 years of experience and the strength of being a Blackstone Real Estate portfolio company, BioMed Realty provides the confidence and partnership that fuel life-enhancing and world-changing innovation. To learn more, visit www.biomedrealty.com.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.